Intuitive Machines: Dilution Is A Drag, But The Backlog Keeps Winning

Q2 operating momentum held up as revenue growth and backlog expanded materially, with backlog reaching ~$1.8B. Organic Q2 bookings showed strong underlying demand beyond acquisition-driven growth, even though adjusted EBITDA weakened. Management flagged dilution as the key risk, but the equity raises appear intended to fund growth rather than address survival.

Analysis

The market should read this as a visibility story, not a clean profitability story. A growing backlog with organic bookings still outpacing the acquisition layer typically supports a higher revenue multiple, but weaker adjusted EBITDA means the near-term debate is about conversion efficiency: can management turn order growth into margin expansion fast enough to offset dilution? If not, the equity raises become a standing overhang on per-share value even if the business is scaling.

Second-order, the balance between funded growth and dilution matters for competitive share. A company that can tap equity to finance capacity, sales coverage, or M&A may temporarily outspend smaller rivals that are constrained by cash flow, which can widen the gap in win rates over the next 1-3 quarters. But if the backlog is long-dated or lower margin, suppliers may gain pricing power and customers may face execution risk, limiting the quality of that growth.

Near term, sentiment can stay positive as long as bookings stay strong; the reversal trigger is any sign that backlog is being “bought” at the expense of margin discipline. Over 6-18 months, the key question is per-share growth versus absolute growth: if dilution persists faster than EBITDA inflects, the multiple should compress even with solid revenue prints. This is a good setup to monitor, but not enough for a high-conviction standalone long without more evidence on conversion rates and capital intensity.

Key Decisions for Investors

• Watchlist, not immediate conviction trade: wait for the next print to see whether gross margin and adjusted EBITDA improve faster than share count. Falsifier: continued dilution with flat-to-down EBITDA margin for 2 consecutive quarters.
• Relative-value idea: long profitable backlog-backed industrial/software compounders and short the unprofitable small-cap growth basket (IWM/ARKK proxy) if the market starts rewarding funded growth over cash burn. This expresses quality over quantity of growth.
• If the stock sells off on dilution despite stable bookings, consider a tactical long only if management reiterates backlog conversion and no further capital raise is implied; otherwise avoid catching the knife.
• If backlog growth decelerates or organic bookings slow next quarter, exit the bullish thesis quickly — the market will likely re-rate this from 'growth at any cost' to 'capital inefficient.'